1 week Ago By ABMN Staff
Nisa Investment Advisors LLC lifted its holdings in Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY – Free Report ) by 15.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.
The firm owned 13,317 shares of the biopharmaceutical company’s stock after buying an additional 1,789 shares during the period. Nisa Investment Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $3,134,000 as of its most recent SEC filing. A number of other institutional investors and hedge funds have also modified their holdings of the business.
Dimensional Fund Advisors LP boosted its position in Alnylam Pharmaceuticals by 4.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 266,206 shares of the biopharmaceutical company’s stock worth $64,702,000 after acquiring an additional 11,027 shares during the period.
AQR Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 92.5% during the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock worth $65,862,000 after purchasing an additional 130,482 shares during the period.
APG Asset Management N.V. grew its position in Alnylam Pharmaceuticals by 38.
8% during the second quarter. APG Asset Management N.V.
now owns 93,565 shares of the biopharmaceutical company’s stock valued at $21,214,000 after purchasing an additional 26,160 shares in the last quarter. MBB Public Markets I LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $2,236,000. Finally, Mackenzie Financial Corp lifted its position in Alnylam Pharmaceuticals by 94.
9% in the 2nd quarter. Mackenzie Financial Corp now owns 36,091 shares of the biopharmaceutical company’s stock worth $8,770,000 after buying an additional 17,576 shares in the last quarter. Hedge funds and other institutional investors own 92.
97% of the company’s stock. Alnylam Pharmaceuticals Price Performance Shares of Alnylam Pharmaceuticals stock opened at $278.76 on Friday.
The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.
69. The company has a market cap of $35.95 billion, a PE ratio of -106.
40 and a beta of 0.34. The firm has a fifty day moving average price of $247.
13 and a two-hundred day moving average price of $260.30. Alnylam Pharmaceuticals, Inc.
has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.
Analyst Upgrades and Downgrades ALNY has been the topic of several research analyst reports. Piper Sandler restated an “overweight” rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th.
William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Bank of America raised their price target on Alnylam Pharmaceuticals from $307.00 to $314.
00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Scotiabank boosted their price target on Alnylam Pharmaceuticals from $305.00 to $310.
00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Finally, Chardan Capital reaffirmed a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st.
One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $298.
61. Read Our Latest Stock Analysis on Alnylam Pharmaceuticals Insider Transactions at Alnylam Pharmaceuticals In other news, CMO Pushkal Garg sold 1,682 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.
98, for a total value of $422,148.36. Following the completion of the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.
86. This represents a 8.79 % decrease in their position.
The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website . Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.
98, for a total transaction of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.
18. This trade represents a 10.02 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . In the last quarter, insiders have sold 21,372 shares of company stock valued at $5,634,205. 1.
50% of the stock is owned by corporate insiders. Alnylam Pharmaceuticals Profile ( Free Report ) Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
See Also Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
